Exelixis (EXEL) Operating Income Growth (3y) (2013 - 2026)
Powered by 
Analysis
Exelixis (EXEL) Operating Income Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 89.72% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 24.14% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 44.54% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 44.34% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -18.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 81.27% |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 47.22% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 47.22% |
| Apr 3, 2026 | 105.81% |
| Jan 2, 2026 | 90.31% |
| Oct 3, 2025 | 42.00% |
| Jul 4, 2025 | 36.65% |
| Apr 4, 2025 | 30.93% |
| Sep 27, 2024 | 38.14% |
| Jun 28, 2024 | 30.90% |
| Mar 29, 2024 | 103.24% |
| Dec 29, 2023 | 49.87% |
| Sep 29, 2023 | 25.53% |
| Jun 30, 2023 | 1.01% |
| Mar 31, 2023 | -18.27% |
| Dec 30, 2022 | -37.89% |
| Sep 30, 2022 | -10.60% |
| Jul 1, 2022 | -3.10% |
| Apr 1, 2022 | -0.52% |
| Oct 1, 2021 | -25.57% |
| Jul 2, 2021 | 12.77% |
| Apr 2, 2021 | -26.82% |